Invention Grant
- Patent Title: Stromal stem cells
-
Application No.: US18329455Application Date: 2023-06-05
-
Publication No.: US11952589B2Publication Date: 2024-04-09
- Inventor: Stephen J. Elliman
- Applicant: Orbsen Therapeutics Limited
- Applicant Address: IE Dangan
- Assignee: Orbsen Therapeutics Limited
- Current Assignee: Orbsen Therapeutics Limited
- Current Assignee Address: IE Dangan
- Agency: Wilson Sonsini Goodrich & Rosati
- Priority: GB 02319 2012.02.10
- The original application number of the division: US15089435 2016.04.01
- Main IPC: C12N5/0775
- IPC: C12N5/0775 ; A61K9/00 ; A61K35/28 ; A61K35/407 ; C12N5/074 ; C12N5/077 ; C12Q1/37 ; G01N33/50

Abstract:
Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
Public/Granted literature
- US20230313142A1 STROMAL STEM CELLS Public/Granted day:2023-10-05
Information query
IPC分类: